As Cancer Immunotherapy Turns 125, WBB Securities’ Steve Brozak Ponders What Investors Can Expect from Biotech Next
5.27.15 | The Life Sciences Report
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this interview with The Life Sciences Report, Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over. For the full article, please click here.